Transmission of Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae: the role of infection control

Abstract

Background The worldwide spread of carbapenemase-producing Gram-negative bacteria (GNB) in healthcare settings is worrying. Of particular concern is the occurrence of Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae (KP). In recent years, several guidelines and recommendations have focused on the control of carbapenem-resistant GNB. It remains, however, unknown to what extent individual infection control measures are effective. Our aim was to critically review the recent evidence regarding the effectiveness of measures to control KPC-KP spread in healthcare settings. Methods Critical review of the literature aiming to evaluate, in accordance with published recommendations, all available studies reporting infection control (IC) measures to control KPC-KP published in the past 5 years. Results Among 11 included studies, the majority consisted of outbreak reports, where application of measures was reported in the absence of control groups. Variability was observed related to the frequency of application of recommended measures for control of KPC-KP. Additional measures were recorded, such as environmental sampling and staff screening, whereas compliance with hand hygiene was measured in relatively few studies. Finally, mortality in patients harbouring KPC-KP was notable, reaching 42.9% of included patients. Conclusions Despite successful control of KPC-KP spread during outbreaks, the impact of individual IC measures is difficult to assess, as the quality of published evidence is low and controlled intervention studies are lacking. The distribution of studies, the number of reported cases and the high mortality rates, clearly show that KPC-KP remains a major healthcare problem worldwide.

Multiple Novel Ceftazidime-Avibactam-Resistant Variants of bla KPC-2 -Positive Klebsiella pneumoniae in Two Patients

“…Nowadays, KPC-KP related-infections are increasing rapidly worldwide ( 16 ). Ceftazidime-avibactam, as one of its most effective antibiotics, has already been clinically approved in the United States since 2015, in Europe since 2016, and in China since 2019, and its rising resistance is predictable with extensive use ( 17 ).…”

Molecular typing methods &amp; resistance mechanisms of MDR <i>Klebsiella pneumoniae</i>

“…KPCs (KPC-2–KPC-13) are the most common carbapenemases found in K. pneumoniae [85] . Immediately after its identification, KPCs spread worldwide and resulted in many outbreaks in Africa, Asia, European countries, and North America [86] – [89] . Bacteria-producing KPCs have progressed and become resistant to multiple antimicrobials, thus limiting treatment choices for managing infections [90] , [91] .…”

TiO2 Nanocomposite Coatings and Inactivation of Carbapenemase-Producing Klebsiella Pneumoniae Biofilm—Opportunities and Challenges

“…The increase in carbapenemase-producing Klebsiella species has led to high hospital mortality and limited treatment options. Hospitals worldwide implement strict measures to limit infection and prevent the spread of the bacterium but, currently, the effectiveness of these measures is still unknown [13][14][15][16]. Recently, more guidelines and recommendations have focused on controlling and preventing carbapenemase-producing Enterobacteriaceae infections.…”